Right Upper Chest Nodule Found

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ariana Pelosci

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 19th 2025

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

$Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.$

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Related Content

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ariana Pelosci

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 19th 2025

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

$Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.$

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.